Londone \u012fsik\u016brusi bioin\u017einerijos bendrov\u0117 \u201eNeobe Therapeutics\u201c pritrauk\u0117 6,1 mln. eur\u0173 pradin\u0117s stadijos (Seed) investicij\u0173. L\u0117\u0161os bus skirtos kurti geneti\u0161kai modifikuotas bakterijas, kurios ardo fizines kli\u016btis, trukdan\u010dias vaistams pasiekti kietuosius navikus.<\/p>\n
Apie sandor\u012f prane\u0161\u0117 \u201eEU-Startups\u201c: investicij\u0173 raundui vadovavo \u201eARC Ventures\u201c, jame dalyvavo \u201eFaber\u201c, \u201eMacmillan Ventures\u201c, \u201eProven Connect\u201c ir \u201eEmpirical Ventures\u201c. Taip pat nurodoma, kad bendras iki \u0161iol pritrauktas finansavimas vir\u0161ijo 9,4 mln. eur\u0173.<\/p>\n
\u201eNeobe\u201c teigimu, net ir pa\u017eang\u016bs v\u0117\u017eio gydymo metodai, \u012fskaitant imunoterapij\u0105, neveikia daliai pacient\u0173 ne vien d\u0117l biologini\u0173, bet ir d\u0117l fizini\u0173 prie\u017eas\u010di\u0173. Aplink navik\u0105 susiformuojanti tanki, pluo\u0161tin\u0117 matrica gali veikti tarsi siena, kurios nei imunin\u0117s l\u0105stel\u0117s, nei vaistai nepaj\u0117gia \u012fveikti.<\/p>\n
Bendrov\u0117 siekia \u0161i\u0105 problem\u0105 spr\u0119sti \u201egyv\u0173 vaist\u0173\u201c principu: nekenksmingos, da\u017enai gamtoje sutinkamos bakterij\u0173 paderm\u0117s b\u016bt\u0173 \u201eu\u017eprogramuojamos\u201c taip, kad patekusios \u012f organizm\u0105 kryptingai keliaut\u0173 \u012f navikus ir i\u0161skirt\u0173 fermentus, galin\u010dius tirpdyti navik\u0105 supan\u010di\u0105 matric\u0105.<\/p>\n
Pasak \u201eNeobe\u201c, suirus \u0161iai apsauginei strukt\u016brai atsirast\u0173 kelias imuninei sistemai ar kitiems prie\u0161v\u0117\u017einiams vaistams patekti \u012f navik\u0105 ir veiksmingiau naikinti v\u0117\u017eio l\u0105steles. Tokiu b\u016bdu, bent teori\u0161kai, b\u016bt\u0173 galima padidinti gydymo efektyvum\u0105 ten, kur iki \u0161iol rezultatai nuvildavo.<\/p>\n
Bendrov\u0117 primena, kad id\u0117ja naudoti bakterijas v\u0117\u017eio gydymui atsirado dar XX am\u017eiaus prad\u017eioje. Ta\u010diau, kaip teigiama, iki \u0161iol buvo sud\u0117tinga sukurti nekenksmingas bakterijas, kurios b\u016bt\u0173 pakankamai saugios ir kartu geb\u0117t\u0173 tiksliai \u201etaikytis\u201c \u012f navikus.<\/p>\n
Tekste nurodoma, kad 2026 metais \u017eurnale \u201eMolecular Cancer Therapeutics\u201c publikuotame darbe \u201eNeobe\u201c bendradarbiavo su Kipro universiteto ir Londono \u201eBarts Cancer Institute\u201c tyr\u0117jais. Buvo vertinamas j\u0173 platformos poveikis trigubai neigiamo kr\u016bties v\u0117\u017eio modeliui, kuris nereagavo \u012f \u012fprast\u0105 imunoterapini\u0173 vaist\u0173 derin\u012f.<\/p>\n
\u201eNeobe\u201c teigimu, viename i\u0161 tirt\u0173 modeli\u0173 viena in\u017einerini\u0173 bakterij\u0173 doz\u0117 l\u0117m\u0117 visi\u0161k\u0105 naviko regresij\u0105, taikant t\u0105 pat\u012f gydym\u0105. Taip pat nurodoma, kad v\u0117lesniu laikotarpiu, pakartotinai testuojant, daugiau navik\u0173 nebesusiformavo \u2013 tai, pasak startuolio, gali rodyti susidariusi\u0105 ilgalaik\u0119 imunin\u0119 atmint\u012f.<\/p>\n
Bendrov\u0117 taip pat prane\u0161\u0117 \u012f komand\u0105 pakvietusi imunoonkologijos ekspert\u0119 dr. Laura Chow, kuri taps vyriausi\u0105ja medicinos vadove (Chief Medical Officer). Ji tur\u0117t\u0173 pri\u017ei\u016br\u0117ti pasirengim\u0105 pirmajam bandymui su \u017emon\u0117mis.<\/p>\n
Skelbiama, kad gautos investicijos leis vystyti pagrindin\u0119 program\u0105 NEO22, vykdyti ikiklinikinius tyrimus ir siekti parai\u0161kos IND pateikimo 2028 metais. Kartu planuojama stiprinti vadov\u0173 komand\u0105 art\u0117jant prie klinikin\u0117s stadijos.<\/p>\n","protected":false},"excerpt":{"rendered":"
Londono \u201eNeobe Therapeutics\u201c pritrauk\u0117 6,1 mln. eur\u0173 kurti bakterijoms, kurios ardo navik\u0173 \u201esien\u0105\u201c ir gali pagerinti vaist\u0173 patekim\u0105 \u012f auglius.<\/p>\n","protected":false},"author":0,"featured_media":69596,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[94],"tags":[54973,54974,4103,54975,54972,1040,25300],"miestas":[],"class_list":["post-69595","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-finansai","tag-arc-ventures","tag-bakteriju-terapija","tag-imunoterapija","tag-molecular-cancer-therapeutics","tag-neobe-therapeutics","tag-startuoliai","tag-vezio-gydymas"],"acf":[],"_links":{"self":[{"href":"https:\/\/cp.snarskis.lt\/index.php\/wp-json\/wp\/v2\/posts\/69595","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cp.snarskis.lt\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cp.snarskis.lt\/index.php\/wp-json\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/cp.snarskis.lt\/index.php\/wp-json\/wp\/v2\/comments?post=69595"}],"version-history":[{"count":0,"href":"https:\/\/cp.snarskis.lt\/index.php\/wp-json\/wp\/v2\/posts\/69595\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cp.snarskis.lt\/index.php\/wp-json\/wp\/v2\/media\/69596"}],"wp:attachment":[{"href":"https:\/\/cp.snarskis.lt\/index.php\/wp-json\/wp\/v2\/media?parent=69595"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cp.snarskis.lt\/index.php\/wp-json\/wp\/v2\/categories?post=69595"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cp.snarskis.lt\/index.php\/wp-json\/wp\/v2\/tags?post=69595"},{"taxonomy":"miestas","embeddable":true,"href":"https:\/\/cp.snarskis.lt\/index.php\/wp-json\/wp\/v2\/miestas?post=69595"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}